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Problem:  Hypertension (HTN) affects over a third of all American adults, 20% of which are 
undiagnosed and untreated. HTN leads to greater morbidity and mortality, placing a person at a 
significantly greater risk for cardiovascular events and chronic kidney disease. The majority of 
those 13 million people with undiagnosed HTN visit their healthcare provider two or more times 
a year. Many patients presenting with elevated blood pressure (BP) measurements in primary 
care clinics in Kansas City often remain undiagnosed for HTN, which is likely to lead to poorer 
health outcomes. No facility-specific protocols exist to encourage follow-up in patients at high 
risk for HTN to address this problem. 
 
Project Aim:  The aim for this quality improvement (QI) project was to determine the 
effectiveness of an educational intervention on the rates of diagnosis and treatment of HTN in a 
primary care clinic in Kansas City.  
 
Project Method:  This QI project used the plan-do-study-act (PDSA) model to determine if 
diagnosis of HTN increased after eight weeks of the implementation of an instrument that 
encouraged follow-up in patients found with a BP of 130/80 or greater. The handout to patients 
with high BP consisted of four components: (1) brief education related to HTN, (2) lifestyle 
changes to decrease BP, (3) instructions for obtaining self-measured BPs, and (4) instructions to 
make a follow-up clinic appointment if their BP remains elevated. Data were gathered to 
evaluate if there was a reduction in the amount of undiagnosed HTN and in the average BPs of 
those seen in the clinic after the intervention. The patients included in this project were required 
to be English-speaking, between the ages 18 and 65, and had to have visited a specific primary 
care clinic in Olathe, Kansas, between May 20 and August 9, 2019. 
 
Findings: A total of 635 patient records were reviewed during the pre- and post-intervention 
phases. The number of undiagnosed HTN patients before the intervention was 91 of 301 
participants, for a total of 30.2%. The number of undiagnosed hypertensive patients after the 
intervention was 120 of 334 participants, for a total of 35.9%. An estimated 424 patients had 
undiagnosed HTN during the eight-week intervention period, but only 233 educational handouts 
were provided. The fact that only 55% of eligible patients received the intervention can be 
explained by patient refusal and lack of staff consistently offering the handout to eligible 
patients. There was no improvement in the pre-intervention means of systolic and diastolic BPs 




    	 2 	
 
Conclusion: Primary care providers will frequently observe undiagnosed HTN. Thus, more 
structured protocols need to be developed to provide more consistent diagnosis and treatment for 
HTN in order to prevent the long-term consequence of HTN. This DNP project did not 
demonstrate a statistically significant improvement in BP measurements or the rate of 
undiagnosed HTN. However, the data indicated a significant proportion of patients seen during 
the project timeline had undiagnosed HTN, suggesting this is a practice problem at this clinic and 
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Hypertension (HTN) is a major health problem in the United States, affecting over a third 
of American adults. Of those affected, nearly 20%, over 13 million people, are unaware they 
have HTN and are therefore not being treated for it (Centers for Disease Control [CDC], 2016; 
Park et al., 2018). Some studies estimate up to 36% of hypertensive patients are unaware of their 
condition (Wall, Hannan, & Wright, 2014). HTN greatly increases an individual’s morbidity and 
mortality, with an increased risk for heart attacks and strokes, as well as other debilitating 
diseases such as chronic kidney disease and heart failure (CDC, 2016). Most individuals with 
undiagnosed high blood pressure (BP) visit their healthcare providers at least twice a year (CDC, 
2016). With the rise in HTN, the CDC, Centers for Medicare & Medicaid Services, and Healthy 
People 2020 have made HTN control a national health priority goal (U.S. Department of Human 
Health & Services, 2016).  
The rates of HTN prevalence and control in Kansas continue to fail to meet the national 
Healthy People 2020 goals of ≤ 26.9% and ≥ 61.2%, respectively (CDC, 2016). Better detection 
and diagnosis of HTN is paramount in order to improve these numbers, as treatment of HTN is 
necessarily preceded by awareness of the problem. A review of 49 studies recently completed by 
the Agency for Healthcare Research and Quality (AHRQ) found strong evidence that self-
measured BP monitoring (SMBP) with additional educational support is more effective than 
routine care in detecting and lowering BP of patients with HTN (U.S. Department of Human 
Health & Services, 2016). No evidence-based protocol for high BP follow-up to increase 
diagnosis and control of HTN currently exists in the Olathe Health Family Clinic – Hedge Lane 
in Olathe, Kansas, a suburb of Kansas City. The purpose of this quality improvement Doctorate 
of Nursing Practice (DNP) project is to increase follow-up of those at risk for undiagnosed HTN 
and thereby improve HTN diagnosis and BP control in a family practice clinic in a suburb of 
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Kansas City.  
Problem Statement 
Hypertension is a significant public health concern. Nearly 75 million Americans have 
HTN. It is the most common cardiovascular disease (CVD) risk factor that leads to end-organ 
damage and life-threatening complications, most notably heart attack and stroke, when untreated 
(Shrivastava, Shrivastava, & Ramasamy, 2014). CVD events account for nearly one of every 
three deaths in the U.S. each year, nearly half of which are preventable (CDC, 2017). HTN also 
results in countless hospital admissions from complications such as heart failure and kidney 
disease (Whelton et al., 2017). In addition to the profound impact HTN has on quality of life, it is 
a significant financial burden on our nation. The annual cost of HTN exceeds $50 billion, over 
$47 billion of which is from direct medical expenses (CDC, 2017).  
National HTN prevalence is a growing problem; 31.6% of Americans had HTN in 2013-
2014 compared to 27.4% in 2001-2002 (CDC, 2016). BP control in those with HTN is equally 
dismaying, with marginally greater than half (54%) attaining sufficient control (CDC, 2016). The 
landscape in Kansas is similar. In 2017, 32.8% of Kansas’s residents reported they had been told 
they have high BP by a health care professional at some point (CDC, 2017).  
Although proper control in those with HTN remains a serious problem, proper detection 
and diagnosis of the disease is a major contributor to the problem of insufficient control. 
Approximately 20% of those who have high BP remain undiagnosed, although the majority of 
them see their health care provider regularly, many twice a year (CDC, 2016). This indicates a 
gap in proper recognition and diagnosis. The first step in improving HTN control is identifying 
all patients eligible for management and having a systematic approach for follow-up of patients 
for the initiation and intensification of therapy (Go et al., 2014). Clear, evidence-based, follow-
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up protocols need to exist for providers to identify those commonly missed (Go et al., 2014). 
One study found that implementation of a protocol to re-evaluate those with high BP resulted in 
a follow-up rate of 65%, nearly a third of which resulted in a HTN diagnosis (Meador, Osheroff, 
& Reisler, 2018). This emphasizes how imperative it is for organizations to have evidence-based 
guidelines in place for BP follow-up to improve diagnosis and treatment of HTN. No formalized 
structure or process currently exists in the Olathe Health Family Medicine facilities. An 
intervention that requires little extra time, personnel, and financial resources is of utmost 
importance in order to be feasible for implementation in busy primary care facilities. A protocol 
for BP follow-up may result in increased diagnosis and treatment of HTN, decreasing high BPs, 
and improving the health outcomes of the patients seen at the Olathe clinic.  
Project Aims 
The aim of this DNP project was to determine the effectiveness of an educational 
intervention on the rates of diagnosis and treatment of HTN in a primary care clinic in a suburb 
of Kansas City. The purpose of the intervention was to improve BP control for adult patients 
seen at the Olathe Health Family Medicine Clinic by improving follow-up of those at risk for 
undiagnosed HTN. The Project Director created a protocol to encourage patients with high BP to 
follow-up to receive diagnosis and treatment for HTN. The protocol was then assessed to 
determine its effectiveness in increasing the rates of HTN follow-up and control on adults seen in 
a suburban family practice setting within three months when compared to current practice. BP 
measurements were evaluated pre- and post-intervention. The expected outcome was for HTN 
follow-up rates to increase resulting in improved BP measurements after the intervention was 
implemented.   




 Hypertension in its simplest terms is when BP, the force of blood pushing against the 
vessel walls of the circulatory system, is consistently too high (American Heart Association 
[AHA], 2016). The BP measurement is made up of two numbers; the top number, the systolic BP 
(SBP), is the pressure in the circulatory system when the heart is pumping blood. The lower 
number, the diastolic BP (DBP), is the pressure in the circulatory system when the heart is in-
between beats.  
In 2017, the American College of Cardiology and American Heart Association (AHA), 
together with nine other professional associations, published updated HTN guidelines, which 
were authored by Paul K. Whelton, M.D. and numerous other medical experts. The first 
comprehensive update since 2003, the new guidelines lowered the limits for HTN diagnosis. 
Under old guidelines, HTN began with BP >140/90; new guidelines now define HTN as 
beginning at 130/80. The lower limits for HTN diagnosis are a result of the review of over 900 
studies, which revealed that cardiovascular complications double when BP remains elevated 
above 130/80. As a result, the 2017 guidelines now define elevated BP as a SBP of 120-129 and 
DBP < 80, stage 1 HTN as SBP of 130-139 or DBP 80-89, stage 2 HTN as SBP >140 or DBP > 
90 and hypertensive crises as SBP >180 and DBP >120 (Whelton et al., 2017).  
Hypertension is diagnosed as either primary or secondary. Secondary HTN is rare, 
accounting for about 5% of HTN cases, and is caused by identifiable disease such as 
hyperaldosteronism, pheochromocytoma, or Cushing’s disease (Garfinkle, 2017; Noel, 1994). 
While the pathophysiology for secondary HTN has a clear, specific mechanism, the cause of 
primary, or essential, HTN is multifactorial, affected by genetic, environmental, and behavioral 
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factors, as well as the failure of inherent control mechanisms (Bolívar, 2013). Some of the 
proposed mechanisms of essential HTN include increased sympathetic nervous system (SNS) 
activity which can be caused by obstructive sleep apnea, obesity, insulin resistance, metabolic 
syndrome, uric acid elevation, and vitamin D deficiency (Saxena, Ali, & Saxena, 2018) Other 
causes include vascular alterations such as endothelial cell dysfunction and disruptions to the 
nitric oxide pathway, and renal system dysfunction including disruptions of to the renin-
angiotensin-aldosterone system (RAAS) as well as excess dietary salt intake resulting in 
increased pressure for natriuresis (Saxena, Ali, & Saxena, 2018). 
HTN is associated with increased sympathetic tone and it is now believed that autonomic 
dysfunction, characterized by impaired parasympathetic tone and increased sympathetic 
function, plays an important role in the development of HTN. The sympathetic nervous system 
(SNS), whose functions are often characterized by the “fight or flight response,” is responsible 
for the release of the powerful vasoactive neurotransmitters epinephrine, norepinephrine, and 
dopamine. The effect on α-, ß-, and dopaminergic receptors leads to increased cardiac output and 
systemic vascular resistance (SVR), that increases BP. Furthermore, the SNS has a complex 
interaction with renal sodium excretion and the RAAS, which are also critical to BP regulation 
(Grassi & Ram, 2016). 
Some of the most common antihypertensive medications prescribed by clinicians for the 
treatment of HTN are angiotensin II receptor blockers (ARBs) and angiotensin-converting-
enzyme (ACE) inhibitors, which work by affecting the RAAS. Renin is a circulating enzyme that 
breaks down angiotensinogen into angiotensin I, which is then further reduced by ACE into 
angiotensin II, a powerful vasoconstrictor. Angiotensin II increases BP in a multitude of ways, 
which can be viewed in Figure 1. It causes vasoconstriction of arteries, raising SVR, and affects 
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the kidneys, influencing multiple ion transporters throughout the tubules, leading to increased 
sodium retention. It also causes increased aldosterone release from the adrenal glands, which 
leads to further sodium and water reabsorption by the kidneys (Saxena, Ali, & Saxena, 2018).  
 
Figure 1. The RAAS is a complex multi-organ system that regulates BP and fluid retention 
(StraightHealthcare, 2018).  
Endothelial cell dysfunction is another key contributor to the pathogenesis of HTN. 
Endothelial cells line the inner surface of blood vessels in the circulatory system and produce 
many enzymes important for BP control. Nitric oxide (NO) is one of the more important 
enzymes released by endothelial cells and the disruption of its normal function is a contributor to 
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the development of HTN. NO is a potent vasodilator which causes relaxation of vascular tone 
and inhibits the proliferation of vascular smooth-muscle cells. Its constant release is responsible 
for maintenance of reduced vascular tone. Endothelin (ET) is another potent vasoactive product 
of endothelial cells. It stimulates basal NO release by endothelial cells and acts on the smooth-
muscle cells of the circulatory system with both constricting and dilatory effects (Majumder & 
Wu, 2014). In hypertensive vasculature NO’s dilatory activity is decreased and ET activity 
increases resulting in vasoconstriction and the remodeling and hypertrophy of vascular smooth 
muscle which both contribute to increased SVR (Saxena, Ali, & Saxena, 2017). Figure 2 shows 
how these enzymes affect the blood vessels and cause hypertrophy and vasoconstriction of the 
vessels, resulting in HTN over time. 
 
Figure 2. Endothelial dysfunction including decreased NO activity, resulting in decreased vessel 
tone relaxation, and increased ET, causing vasoconstriction, remodeling, and hypertrophy of 
vessels, results in vascular changes which lead to HTN (Harvey, A., Montezano, A. C., Touyz, 
R. M., 2015).  
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There are multiple other mechanisms in the body, which may also be implicated in HTN 
development but by which exact mechanisms are not yet clearly understood. For the sake of 
thoroughness and brevity they will only be mentioned here. For example, there is evidence of 
impairment of reflex mechanisms including arterial baroreceptor reflexes, cardiopulmonary 
reflexes, and chemoreceptor receptors, in the setting of HTN. Other humoral systems may also 
contribute to the development of HTN, including vasopressin, leptin-melanocortin system, atrial 
natriuretic peptides, and brain natriuretic factors (Grassi & Ram, 2016). In addition, oxidative 
stress has an important role; the up regulation of oxidants, or reactive oxygen species (ROS), has 
been connected to activation of angiotensin II and decreased NO activity (Majumder & Wu, 
2014). The diagram in shown in figure 3 outlines the cascade of changes that contribute to the 
development of HTN. 
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Figure 3. A diagram of the many factors leading to HTN (Pathophysiology of Hypertension, 
2008).   
Burden of Hypertension  
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Affecting over a third of all American adults, HTN is undiagnosed and untreated in 
approximately 20-36% afflicted (CDC, 2016; Wall, Hannan, & Wright, 2014). HTN, which 
increases the risk for a multitude of debilitating health problems such as chronic kidney disease 
and heart failure, is the leading cause of heart disease and strokes (CDC, 2016). It is one of the 
top ten most costly diagnoses in the U.S., with stroke and heart disease, its two most common 
complications, ranking number one and number four, respectively (Kamal, 2017).  
Improving HTN control is a national health priority and was selected as the only Leading 
Health Indicator for Healthy People 2020’s Heart Disease and Stroke improvement goals (Park 
et al., 2018). In addition, the CDC and the Centers for Medicare & Medicaid Services jointly 
launched a large-scale initiative in 2012, titled Million Hearts, aimed at encouraging healthcare 
organizations to develop protocols to reduce HTN with the goal of preventing one million 
strokes and heart attacks over five years. BP control is one of the four core recommendations of 
their “ABCS”, which stands for Aspirin when appropriate, BP control, Cholesterol management, 
and Smoking cessation (U.S. Department of Human Health & Services, 2016).  
Need for Hypertension protocols 
Whelton et al. (2017) found that only 15.8% of patients with undiagnosed HTN received 
a prescribed medication to control their BP whereas 92.6% of those with diagnosed HTN 
received treatment. This demonstrates that a diagnosis of HTN is an important aspect of 
improved BP control. Although protocols exist for titrating anti-hypertensive medications to 
control BP, very few organizations have standardized processes that outline a follow-up process 
for patients with high BP without a diagnosis of HTN. Re-evaluation of patients with a high BP 
on one occasion is important, as current recommendations necessitate two or more high BP on 
two or more occasions to diagnose HTN (Whelton et al., 2017). Meador et al. (2018) found that 
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implementation of a protocol to re-evaluate those with HBP resulted in a follow-up rate of 65%, 
nearly a third of which resulted in a HTN diagnosis.  
Another large randomized trial highlights the issue of providers’ conservative approach 
to HTN treatment and the importance of protocols. Hyman et al. (2012) found that although 90% 
of healthcare providers reported they sought a BP goal of 130/80 most providers did not intensify 
treatment until SBP was 150 or greater. This study proposed that three factors affect providers’ 
decisions to not intensify BP treatment; providers’ uncertainty of patients’ out of office BPs, 
their medication adherence, and their follow-through with lifestyle modifications. One way to 
address this is to improve the number of patients who monitor their BP outside of the clinic using 
home BP monitoring systems.  
Home BP monitoring systems 
Home BP monitoring (HBPM) has been found by many studies to be more closely 
correlated with the “golden standard” 24-hour ambulatory BP monitoring (ABPM), than in office 
blood pressure monitoring (OBPM) (Breaux-Shropshire, Judd, Vucovich, Shropshire, & Singh, 
2015). The AHA, the American Society of Hypertension, and the Preventive Cardiovascular 
Nurses Association support HBPM being incorporated into usual care (Breaux-Shropshire, Judd, 
Vucovich, Shropshire, & Singh, 2015). In fact, the AHA has recommended the routine use of 
HBPM for over a decade (Pickering et al., 2005). This is unsurprising, as HBPM is a better 
predictor of cardiovascular mortality (Breaux-Shropshire, Judd, Vucovich, Shropshire, & Singh, 
2015). Another part of the benefit of HBPM may be due to its patient-centered approach. Self-
monitoring encourages patients to claim their role in improving their health; as many authors 
have noted, certainly by serving as a reminder to improve medication adherence, but perhaps 
also by increasing consciousness and encouraging healthy lifestyle changes. This is further 
    	 14 	
 
supported by the fact that patients randomized into a HBPM group, without any antihypertensive 
medication adjustments, demonstrated improved BP control to those receiving routine OBPM 
(Fuchs et al., 2012).  
Furthermore, HBPM overcomes some of the failures of OBPM, including its low 
sensitivity, as well as its inability to detect white coat HTN and masked HTN (Breaux-
Shropshire, Judd, Vucovich, Shropshire, & Singh, 2015). This is important, as white-coat and 
masked HTN both increase a patients’ cardiovascular risk (Mancia, Facchetti, Bombelli, Grassi, 
& Sega, 2006). Lastly, another significant benefit conferred by HBPM that should not be 
overlooked, is that it increases the number of BP readings a provider on which to base treatment 
decisions, bolstering their confidence in the accuracy of their patients’ typical BP and increasing 
their likelihood of properly treating. 
Accurate BP measurements 
           Although HBPM is important, OBPM will always remain a critical part of diagnosing and 
managing HTN. The new 2017 guidelines stress the importance of ensuring accurate 
measurements, for both at home and in clinic BP measurements. These guidelines include 
directions that the patient sit quietly for at least five minutes before measurement, remain still 
during the reading, avoid smoking, caffeine, or exercise for the 30 minutes prior to the reading, 
empty their bladder beforehand, and sit comfortably with legs uncrossed, both feet on the floor. 
Further measures include support of the limb used to measure BP, appropriate arm and cuff 
position (arm resting so that cuff is at heart level), and use of the correct BP cuff size, placed on 
bare arm, not over clothing. The 2017 recommendation is to take two to three readings in both 
arms and using the higher reading to provide the most accurate estimate. Lastly, proper 
calibration of the device used for BP measurement is vital. For HBPM, patients should be 
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advised to validate their home instrument by bringing it to the office to be calibrated with the 
office BP measurement. Patients taking HBPM should also be educated that the ideal time to 
measure BP is in the morning before medication and in the evening before supper, a minimum of 
two readings one minute apart. Either using a device that has memory capability or keeping 
fastidious records of these BP readings is obviously an essential part of utilizing HBPM as well 
(Whelton et al., 2017). 
Patient education on lifestyle changes 
Although lifestyle change is the first recommended treatment for HTN, the education a 
patient receives regarding lifestyle changes varies greatly from one provider to the next. This 
education is paramount if a patient is to succeed with reducing their BP through lifestyle 
changes. Recent 2017 guidelines enumerate the lifestyle changes which should be recommended 
to patients and cite that these changes can reduce hypertensive patients SBP by 4 to 11 mm Hg. 
The DASH diet, with increased potassium and magnesium intake from fruits, vegetables, whole 
grains, and low-fat dairy products, is a core dietary recommendation, as is sodium restriction 
(Wheton et al., 2017). Salt restriction is an important aspect of HTN control since BP rises in 
response to a high dietary salt intake, in order to effectively excrete sodium through the kidneys 
(Garfinkle, 2017; Bolívar, 2013). Another recommendation for HTN is for an individual to 
exercise, 90 to 150 minutes a week. These diet and exercise changes should also help overweight 
and obese patients lose weight. A decrease in BP by 1 mm Hg in SBP can be expected for every 
1 kg of weight loss. Education on alcohol restriction should be no more than two drinks per day 
for men and no more than one drink per day for women. Lastly, resources should be provided to 
smokers to aid them in smoking cessation (Wheton et al., 2017).  




Conceptually, HTN is defined as a higher than normal BP caused by increased cardiac 
output and/or SVR (AHA, 2016). Operationally, the new 2017 guidelines for HTN will be used, 
and anyone presenting to the clinic with a systolic BP of 130 mm Hg or greater or a diastolic BP 
of 80 mm Hg or greater will be given the handout for patients who are hypertensive (Whelton et 
al,, 2017). 
Educational Intervention 
 Conceptually, an educational intervention is a change process in a healthcare system with 
a goal of improving quality of care and patient outcomes (Evidence-based Practice Center 
Systematic Review Protocol, 2012). An educational intervention is specifically using education 
of patients and/or staff to effect those changes. Operationally, in this project the intervention is 
the education provided to the providers, the guidelines for HTN diagnosis, and the 
recommendations for follow-up, as well as the education included in the handout to patients (see 
Appendix C). 
Family Practice Clinic 
 A family practice clinic is an outpatient setting in which patients across the lifespan 
receive general medical, or “primary” care. In this DNP project the family practice clinic is the 
Olathe Health Family Medicine (Hedge Lane) in Olathe, Kansas, a suburb of Kansas City. It 
consists of both a primary care side, in which a physician sees patients with an appointment only, 
and an urgent care side, in which nurse practitioners have same-day appointments available and 
see walk-in patients. 




This quality improvement (QI) project utilized the Plan-Do-Study-Act (PDSA), which is 
a well-known, highly recommended tool for improving patient care in clinic settings (Agency for 
Healthcare Research and Quality, 2013). The Million Hearts Change Package for Clinicians 
specifically recommends the PDSA cycles method for implementing the new evidence to 
improve HTN control. Studies indicate that a systematic approach to HTN management can 
significantly improve HTN-related care processes and outcomes (CDC Hypertension Control 
Change Package for Clinicians, 2015). The PDSA format provides that systematic approach to 
follow. It allows for rapid testing and determination of whether a new change results in 
improvements in a particular setting (CDC Hypertension Control Change Package for Clinicians, 
2015). It is essentially a method for testing a change in the real work setting; it is “action-
oriented learning” (Agency for Healthcare Research and Quality, 2013). The four parts are as 
follows: (1) Plan: define the objective, questions, and predictions and plan data collection to 
answer these questions. (2) Do: Carry out the plan, collect the data, and begin analysis of the 
data. (3) Study: Compare the analysis of the data, compare data with predictions, and summarize 
what was learned. (4) Act: Plan the next cycle; decide whether the change can be implemented 
(Morelli, 2016). Please see appendix A for the PDSA cycle diagram customized to this DNP 
project. 
Applying the PDSA to this QI project, the “plan” portion is accomplished by outlining 
the plan in this proposal and discussing the project with the clinic healthcare providers. The “do” 
aspect was accomplished over the three-month period where the Project Director conducted the 
QI project in a local family medicine clinic. The Project Director collaborated with the statistical 
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department to analyze pre- and post-intervention data and compared with expected findings. The 
data were evaluated to determine the effectiveness of the intervention and to summarize those 
findings, completing the “study” piece of the PDSA cycle. To fulfill the “act” portion, the 
information regarding findings will be disseminated to the staff at the clinic site. The educational 
resources that were used in the QI project will be provided to the administration at Olathe Health 
for continued use in that clinic. In addition, the Project Director will disseminate the findings at 
the DNP Public presentation.  
The creator of the PDSA, the Institute for Healthcare Improvement, adds three 
recommended questions when implementing an intervention: (1) What are we trying to 
accomplish? (2) How will we know that a change is an improvement? and (3) What changes can 
we make that will result in improvement (CDC Hypertension Control Change Package for 
Clinicians, 2015)? To answer those three questions, the goal of this DNP project was to improve 
HTN control by increasing diagnosis and treatment of undiagnosed HTN through improved 
follow-up by implementation of a protocol to increase follow-up of patients with high BP. The 
evaluation to determine if the implemented protocol is effective at improving this goal in the 
clinic is whether or not it results in improved patient follow-up for HTN, demonstrated by 
increased diagnosis of HTN and decreased BPs in the patients.  
Setting  
The setting for this project is an Olathe Health Family Medicine clinic in the suburbs of 
the Kansas City metropolis. This family practice clinic has approximately 1,500 clinic visits a 
month and sees patients across the lifespan with all types of payment, including all insurances, 
Medicaid and Medicare, and self-pay. The clinic includes a walk-in side with an advanced 
practice registered nurse or physician assistant seeing those patients and an appointment only 
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primary care side with a physician. All patients in the clinic were included, whether scheduled 
for a primary care visit with the physician or nurse practitioner in the “walk-in” clinic. After the 
patient checks in at the clinic desk, the registered nurse (RN) places the patient in a clinic room 
before the healthcare provider enters. The RN obtains BP, respiratory rate, temperature, and 
completes other screening questions. If the patient’s BP is 130/80 or greater, the nurse offered 
the project handout on HTN to the patient. The handouts were distributed to the patient if they 
have HTN regardless of whether they have a diagnosis of HTN. The handout consisted of a one-
page document with patient education on HTN, as well as a place for the nurse to write their 
OBPM from that visit, and instructions on obtaining a minimum of two additional BPs at home 
or at a local pharmacy. 
Sample Population 
A convenience sample was utilized for this project. All patients between 18 and 65 years 
of age seen in the clinic for any reason, a scheduled appointment on the primary care physician 
side or an acute visit on the walk-in side, who have a BP of 130/80 or greater, was offered the 
intervention. Only non-English speaking patients or those with cognitive or physical disability 
that prohibits their ability to understand the educational intervention were excluded from 
participation. All adult patients at the clinic sit for all reasons, whether an annual physical, an 
acute visit, or general follow-up visit, were included. The clinic averaged 159 patients a week 
with 53 of those presenting without a diagnosis of HTN but with a BP ≥ 130/80, which came to a 
third of all patients seen. A total of 233 educational handouts were given during the 8-week 
intervention period to an estimated 424 eligible patients. The fact that about 55% of eligible 
patients received the intervention can be explained by patient refusal and a lack of staff 
identifying eligible participants and offering the educational handout. 
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Implementation  
The intervention was implemented into standard workflow in the follow way. When the 
RN roomed the patient they obtained a BP following guidelines for accuracy in Appendix B. If 
the SBP was ≥ 130 or DBP ≥ 80 the RN would ask the patient if they have ever received a 
diagnosis of HTN. If they answered no, they were offered the handout (as in Appendix C), and 
were asked to schedule a follow-up appointment within the next 4 weeks when they checked out 
to encourage a return visit.  
The handouts given to patients, as shown in Appendix C, include a definition of high BP, 
its common signs and symptoms, and the complications of uncontrolled HTN. They include a 
place for the nurse to write in the patient’s BP measurement taken that day and have instructions 
for obtaining a minimum of two BPs before their next visit and a place to record those. The 
handouts also include instructions on lifestyle changes to improve BP and encourage patients to 
schedule a follow-up appointment within 4 weeks. The handouts state that if home BPs are less 
than 130/80 the patient can cancel their appointment and continuing monitoring BP at home with 
lifestyle changes. The reverse of that sheet has more details on the AHA endorsed DASH diet, 
which is the acronym for Dietary Approaches to Stop Hypertension (Whelton et al., 2017). Two 
hundred sheets were initially printed, and the supply was checked periodically during the 
intervention, additional were printed as needed and a total of 233 were given to patients. The 
handouts were stored by the nurses’ desk to serve as a reminder, since the nurses use their 
laptops for intake assessments. The nurses took a handout with them every time they roomed a 
patient, and left it with the patient if their BP was 130/80 or greater.  
 The nurses and providers were provided education on the intervention during their staff 
meeting May 31, 2019. The education consisted of reviewing the dangers of undiagnosed, 
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untreated HTN, the reliability of HBPM, the importance of patient education, as well as specific 
details regarding the timeline of the intervention and the aims of the project. The PowerPoint 
presentation used for the education of staff is included in Appendix D. The staff meeting 
presentation took approximately 15 minutes total and then the providers and nurses were met 
with individually after the meeting for no more than 5 minutes each to address any additional 
questions. In the individual meetings with the nurses a quick review on the elements necessary 
for an accurate BP reading were reviewed, using Appendix B, BP Accuracy and Variability 
Quick Reference, as a guide. Laminated copies of the quick reference were left at both of the 
nurses’ station for consultation and reinforcement. The infographic in Appendix E, which 
describe what high BP is and enumerate lifestyle changes to improve HTN, were hung on the 
wall in every patient room at that time as well.  
Data Collection Method & Protected Health Information 
The Project Director completed an Electronic Medical Record (EMR) review on all 
patient visits over two two-week periods, pre- and post-intervention. The only data collected was 
BP measurements and the patients’ status of a HTN diagnosis or treatment. For all patients seen 
during those two-week periods, their BPs and their HTN diagnosis status were recorded in an 
Excel software program on a secure laptop computer. The data obtained was organized into one 
of four categories: (1) Those with a normal BP and no diagnosis of HTN; (2) Those with a 
diagnosis of HTN receiving treatment; (3) Those with a high BP and a diagnosis of HTN; and (4) 
Those with a high BP but no diagnosis of HTN. The BPs collected during those two-week 
periods was then averaged to determine the mean BP of all patients seen during those two 
periods. The pre- and post-intervention means was then compared to determine if this QI project 
was effective in improving BPs of patients at this clinic.  
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The data regarding patients BPs and HTN diagnosis status are located within the Olathe 
Health Family Medicine clinic’s EMR and was gathered at the clinical site and stored 
electronically on a password protected laptop. The Project Director will be the only one 
responsible for data collection. The information recorded was de-identified being sure to exclude 
names, birth dates, account numbers, or any other identifying information. No protected health 
information (PHI) will be stored. 
Timeline 
This DNP project was conducted over a three-month period and was reevaluated monthly 
to ensure the project was being completed as planned. The initial data collection period occurred 
prior to the intervention period, from May 15th thru May 29th, 2019 (Phase 1). The next data 
collection period was eight-weeks later to allow adequate time for the educational intervention to 
be implemented and patients given time to reassess their BP and return to the clinic for treatment 
if indicated (Phase 2). The final data collection occurred July 29th through August 9th, 2019. The 
DNP project was actively conducted over the course of three months, with preparation, 
evaluation, and dissemination work occurring before and after for a total of 30 weeks (Table 1),  
Table 1: Timeline for DNP Project 
Stage Activity Estimated 
Duration 
Start Date End Date 
Project Preparation § Finalize project design & 
protocol 
§ Hold staff training 
meetings 
§ Disseminate educational 
information 
2 weeks 5/17/19 5/31/19 




2 weeks 5/20/19 5/31/19 
Implementation Provide handout to every 
patient with BP ≥ 130/80  
8 weeks 6/3/19 7/26/19 




2 weeks 7/29/19 8/9/19 




§ Analyze data results 
§ Complete DNP project 
paper with evaluation of 
findings 
§ Share results with clinic 
staff and public 
17 weeks 8/12/19 12/9/19 
  
Ethical Considerations 
A Quality Improvement Determination was submitted to the Human Subjects Committee 
for review at the University of Kansas Medical Center. The Human Subjects Committee ensures 
that the rights, safety, and welfare of all subjects who are included in the DNP project are 
maintained. There are no physical, social, or financial risks anticipated for the participants. 
Patients’ participation is voluntary, based on their decision to receive the handout, so signed 
consent will not be necessary. Patient identifiers will not be used in the data collection or 
analysis period, and those who chose not to participate will still receive standard clinic care.  
Evaluation 
Pre- and post-intervention data were compared and evaluated for two specific variables. 
First, the mean pre- and post-intervention BPs were compared to assess for any improvement in 
BP measurements after the educational intervention. Secondly, the number of patients sorted into 
the fourth category of having a hypertensive BP without a diagnosis of HTN was compared to 
assess for a decrease in the number of undiagnosed hypertensive patients. The pre- and post-
intervention means were then compared to determine if this QI project was effective in 
improving BPs of patients at this clinic.   
Results 
The total number of eligible patients evaluated in both pre- and post-intervention phases 
was 635 adults, including 301 in the pre-intervention phase and 334 in the post-intervention 
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phase. Average BP prior to intervention was 121.1/76.3 mm Hg. The average BP after 
intervention was 122.3/78.6 mm Hg. The number of undiagnosed HTN patients before 
intervention was 91 of 301 participants, for a total of 30.2%. The number of undiagnosed 
hypertensive patients after the intervention was 120 of 334 participants, for a total of 35.9%. This 
increase in undiagnosed HTN patients is the opposite of the expected outcome. Consultation with 
the department of biostatistics revealed that not all data groups met the Shapiro-Wilk test for 
normality. Due to this, the Wilcoxon rank sum test with continuity correction was not determined 
to be valid either. The systolic BP had no significant difference between pre and post 
intervention and the diastolic BP had a slight decrease post intervention compared to pre, which 
is opposite of the expected outcome (B. Liu, personal communication, October 18, 2019).  
Limitations 
The design of this project does have limitations that affect the reliably of result 
interpretation. The most significant limitation to this project is the inability to determine if the 
patients who were included in the pre-intervention phase were included in the post-intervention 
group evaluation. The patients in the first phase were not required to reschedule an appointment 
during the second phase comparisons, thus the differences between the two groups is severely 
limited. Additionally, this DNP project was conducted in one clinic and as such is not 
statistically generalizable. 
Another consideration in the limitations of this project is the extremely variable nature of 
a BP measurement even when comparing the same patient group. Many factors effect BP 
measurement, including BP measurement technique. Control of the variable of technique was 
attempted by completion of education with the nurses regarding proper technique before the 
project began. The education of nurses regarding BP measurement techniques prior to the start of 
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the eight-week intervention period may have led to more accurate BPs. However, increased 
accuracy of BP by nurses is more likely to have led to a decrease in BP measurements as 
opposed to an increase, which was observed in this project. BP techniques such as allowing time 
for the patient to rest before obtaining measurement, having their back and feet supported, 
placing the cuff on an unclothed, supported arm, should provide more accurate BP 
measurements. There are other variables that could have also influenced BP readings, such as 
patient stress, pain, and bladder fullness that are known to increase BP and are difficult variables 
to control.  
Lastly, the time period is also a limitation in this project. The intervention was 
implemented for a total of 8 weeks with 2 weeks before and 2 weeks after being used for pre- 
and post-intervention data collection periods. A longer project runtime would allow for more 
data collection points that could increase the likelihood of statistically significant results. Also, 
only a little more than half of the eligible participants were provided the intervention, suggesting 
that perhaps the staff did not consistently offer the handout to eligible patients. Although the 
Project Director had a couple visit sites for check-ins to ensure the project was being conducted 
properly and to answer any questions from staff, more frequent check-ins might have improved 
the number of eligible patients given the intervention. This could also be impacted by possible 
use of float nursing staff as well, who were not trained in the intervention. The Project Director 
did find that several handouts were provided to patients and they refused them. 
Application 
 Although the analyzed data post-intervention did not demonstrate the intended aims of 
this DNP project, it provided valuable information, particularly about the prevalence of 
undiagnosed HTN seen in patients at this clinic. Of all patients assessed during the pre- and post-
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intervention phases, an average of 33.3% of the patients had high BP (≥130/80 mm Hg) without 
a diagnosis of HTN. This rate is much higher than the CDC’s estimate that 20% of the 
population is unaware and untreated for HTN (CDC, 2016). However, this estimate has been 
cited in the literature, with some studies estimating up to 36% of HTN patients being unaware of 
their condition (Wall, Hannan, & Wright, 2014).  
 This DNP project also provides valuable information to begin a standardized follow-up 
protocol for patients with high BP without a HTN diagnosis. Although more research is needed 
to determine what educational intervention leads to the greatest impact on HTN diagnosis and 
treatment, this project contributes to the practice by providing one method of intervention for 
comparison. In addition, this project increased provider and nurse awareness of the problem of 
undiagnosed HTN. However, frequent re-education is necessary to reinforce the importance of 
treating this disease. Education on evidence-based practice for HTN diagnosis and treatment 
should be provided to the staff every few months.  
Dissemination 
 Dissemination is an important aspect of any scholarly project (Chism, 2016). As 
discussed, this project provides insight into the necessary components of a protocol for high BP 
follow-up. It also presents challenges and areas future projects may be able to address with 
improved, statistically significant outcomes, and will hopefully assist with design of future 
protocols for high BP or other chronic diseases. Dissemination will occur by sharing the 
project’s results with the clinic’s staff at their monthly staff meeting, as well as being presented 
at a public forum for DNP projects attended by fellow DNP students and faculty.  
Conclusion	
Since primary care providers will frequently observe undiagnosed HTN, more structured 
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protocols should be in place to provide more consistent diagnosis and treatment for HTN in order 
to prevent the long-term consequences (Go et al., 2014). This project was conducted since there 
was no such protocol to encourage follow-up for patients at high risk of HTN in the Olathe 
Health family medicine clinics. The intervention implemented consisted of two educational 
pieces: (1) Education of providers on the high rates of undiagnosed HTN, the guidelines for HTN 
diagnosis, and the recommendations for follow-up of patients with a high BP reading and (2) an 
educational handout offered to eligible patients to encourage follow-up for high BP with the goal 
of improved diagnosis and treatment of HTN. Although the results of this DNP project were not 
statistically significant, the data indicated a significant proportion of patients seen during the 
project timeline had undiagnosed HTN (> 33%), suggesting this is a practice problem that 
requires continued attention and should be the focus of future DNP projects.   
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Appendix C  
High BP Handout 
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 Appendix D 
PowerPoint Slides for Educational Intervention for Staff 
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Appendix E 
                                                       BP Infographic 	
 
Note. From “High blood pressure,” by J. D. Bisognano, & K. C. Ferdinand, 2017, CardioSmart 
American College of Cardiology. 
